S2P fundamentals
An in-depth look to SIMCERE PHARMAC. GRP LTD operating, investing, and financing activities
S2P free cash flow for H2 23 is 5.39 M EUR. For 2023, S2P free cash flow was -5.49 M EUR and operating cash flow was 56.44 M EUR.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
TTM